FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Stock index futures point to flat to higher open

LONDON (Reuters) - Stock index futures pointed to a mixed open on Wall Street on Monday, with futures for the S&P 500 and Nasdaq 100 up 0.1 and 0.2 percent respectively by 0856 GMT, while those for Dow Jones were steady.

* The U.S. stock market closed higher on Friday, with the S&P 500 adding 13.18 points, or 0.88 percent, to 1,515.60 <.spx>, after comments from Fed officials allayed fears that the central bank would curtail stimulus measures.

* Prospects of continued stimulus also lifted Asian and European equity markets on Monday, with the EuroSTOXX 50 benchmark of euro zone blue chips up 0.7 percent <.stoxx50e>. However, uncertainty over the outcome of Italian elections, which close on Monday, kept a lid on the gains.

* With days left before $85 billion is slashed from U.S. government budgets, the White House on Sunday issued more dire warnings about the harm the cuts will do to Americans. But Republicans, who advocate budget cuts, said the warning was overplayed and called on President Barack Obama to apply what is known as the "sequester" in a more careful way, rather than slashing budgets across the board.

* A relatively light calendar features the Chicago Fed's national activity index for February at 1330 GMT, alongside earnings from Autodesk Inc and Lowe's Companies.

* Barnes & Noble Inc Chairman Leonard Riggio is considering a bid for the company's bookstore business, the Wall Street Journal reported on Sunday, citing people familiar with the situation.

* Disney's movie "Brave" won the Oscar on Sunday for Best Animated Feature.

* BlackRock Inc. , the world's largest money manager, has got approval from the U.S. securities regulator to list a copper-backed exchange-traded fund, potentially getting the jump on JPMorgan, whose listing of a similar product has been delayed by industry objections.

* Knight Capital Group , which recently agreed to be bought for $1.4 billion by Getco Holding Co, has struck a deal to sell its credit-brokerage unit to Stifel Financial Corp , according to a person familiar with the matter.

* Hewlett-Packard Chairman Ray Lane and fellow board members plan to meet with about 20 of the computer maker's big investors Monday in hopes of heading off a campaign to unseat Lane and two other directors, the Wall Street Journal reports.

* Office Depot Inc said late on Friday that following talks with the largest holder of its common stock, Starboard Value LP, it is extending the deadline for nominating candidates for its board at its annual meeting.

* Dick's Sporting Goods Inc shares could rise 23 percent within the next year if the largest publicly traded U.S. sporting goods retailer continues to boost profit at a mid-teens percentage rate, Barron's said.

(Reporting By Toni Vorobyova; Editing by Hugh Lawson)

Read More..

South Korea's new president demands North drop nuclear ambitions

SEOUL (Reuters) - South Korea's new president Park Geun-hye urged North Korea on Monday to abandon its nuclear ambitions, and to stop wasting its scarce resources on arms, less than two weeks after the country carried out its third nuclear test.

In her inauguration speech, the country's first female president, also called on South Koreans to help revive the nation's export-dependent economy whose trade is threatened by neighboring Japan's weak yen policy.

Park, the 61-year-old daughter of South Korea's former military ruler Park Chung-hee, met with the father of North Korea's current ruler in 2002 and offered the impoverished and isolated neighbor aid and trade if it abandoned its nuclear program.

"I urge North Korea to abandon its nuclear ambitions without delay and embark on the path to peace and shared development," Park said after being inaugurated on Monday.

Park, usually an austere and demure figure in her public appearances, wore an olive-drab military style jacket and lavender scarf on Monday and smiled broadly and waved enthusiastically as a 70,000 strong crowd cheered her.

Rap sensation Psy was one of the warm up acts on an early spring day outside the country's parliament and performed his "Gagnam Style" hit, but without some of the raunchier actions.

Park's tough stance was supported by the partisan and largely older crowd at her inauguration.

"I have trust in her as the first female president ... She has to be more aggressive on North Korea," said Jeong Byung-ok, 44, who was at the ceremony with her four-year-old daughter.

PARK FACES CHOICE: PAY OFF PYONGYANG OR ISOLATE NORTH

North Korea is ruled by 30-year-old Kim Jong-un, the third of his line to hold power in Pyongyang and the grandson of a man who tried to assassinate Park's father.

The North, which is facing further U.N. sanctions for its latest nuclear test, which was its biggest and most powerful to date, is unlikely to heed Park's call and there is little Seoul can do to influence its bellicose neighbor.

Park's choices boil down to paying off Pyongyang to abandon its nuclear weapons plan, which would cost hundreds of millions of dollars and failed in 2006 when the North exploded its first nuclear bomb. Alternatively, Seoul could try to further isolate the North, a move that resulted in the 2010 sinking of a South Korean ship and the shelling of a South Korean island.

Referring to the fast economic growth under her father's rule, which drove war-torn South Korea from poverty to the ranks of the world's richest nations, Park urged Koreans to re-create the spirit of the "Miracle on the Han".

Park wants to create new jobs, in a country where young people often complain of a lack of opportunities, and boost welfare, although she hasn't spelled out how she will do either.

Growth in South Korea has fallen sharply since the days of Park's father who oversaw periods of 10 percent plus economic expansion. The Bank of Korea expects the economy to grow just 2.8 percent this year and 2.8 percent in 2014.

Park also faces a challenge from a resurgent Japan whose exports have risen sharply after new Prime Minister Shinzo Abe embarked on a policy to weaken the yen currency.

The won has jumped five percent in 2013 against the yen after a 23 percent gain in 2012, boosting the competitiveness of Japanese exports of cars and electronics against the same goods that South Korean firms produce.

Park last week said she would take "pre-emptive" action on the weak yen, but has yet to specify what action she will take.

(Additional reporting by Jack Kim; Editing by David Chance and Michael Perry)

Read More..

LG aims to raise smartphone sales by 52 percent

SEOUL, South Korea (AP) — LG Electronics Inc. is aiming to raise its smartphone sales by more than half this year as it makes a shift from basic phones to high-end devices after lagging competitors for several years.

The South Korean company aims to sell more than 40 million smartphones in 2013, it said in a statement on Monday. LG shipped 26.3 million smartphones in 2012, fewer than HTC Corp. and Research In Motion Ltd. which each shipped more than 32 million smartphones.

To meet the sales goal, LG will release handsets in all price ranges from high-tier to affordable models and go all out in both developed and emerging markets.

“We aim to improve profitability and also to become a top-tier smartphone brand,” Park Jong-seok, head of LG’s mobile phone business, told reporters at a mobile industry fair in Barcelona, according to the statement.

LG faces similar challenges to other second-tier smartphone vendors. They are squeezed by the two smartphone giants — Samsung Electronics Co. and Apple Inc. — that are dominating most of the profit in the smartphone industry and also by Chinese makers that are expanding in the smartphone markets of fast-growing emerging countries.

But LG hopes to make its Optimus brand stand out by drawing on technologies from other parts of the LG empire. The company is the largest shareholder in LG Display Co. and has collaborated with other LG affiliates on batteries and cameras.

LG was the world’s third-largest maker of cellphones in 2009 but was caught off guard by the popularity of smartphones. In the fourth quarter of 2012, LG sold fewer phones than Chinese rivals Huawei Technologies Ltd. and ZTE Corp., which are expanding shipments of their cheaper smartphones.

Its mobile communications division was profitable for the first time in three years last year as it moved its focus from basic phones to lucrative smartphones.

Wireless News Headlines – Yahoo! News

Title Post: LG aims to raise smartphone sales by 52 percent
Url Post: http://www.news.fluser.com/lg-aims-to-raise-smartphone-sales-by-52-percent/
Link To Post : LG aims to raise smartphone sales by 52 percent
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment

Read More..

Relive the Best One-Liners and Tweets from the Oscars!

02/25/2013 at 12:00 AM EST

Jennifer Lawrence tumbled – to a standing ovation. Ben Affleck tearfully won Best Picure for Argo. And you all loved – or loved to hate – Oscar host Seth MacFarlane.

Yep, the Oscars are over, but it doesn't mean we're done talking about it! You can relive the best of the night! Check out what celebs, readers (and you!) had to say about the musical numbers, speeches – and a certain reigning Sexiest Man Alive! – on Twitter last night.

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Samsung sets sights on iPad mini with new Galaxy Note 8.0 tablet

Samsung (005930) is finally gaining some momentum in the tablet market after a slow start with the original Galaxy Tab, which launched in late 2010. The South Korean consumer electronics giant now has a number of slates available in the 7- and 10-inch ranges, but Apple’s (AAPL) 8-inch iPad mini opened new doors for mid-size tablets following its release this past November. Samsung was already putting a mid-range tablet together when the iPad mini debuted last year, and now the company is finally ready to take the wraps off its latest Note series device: The Galaxy Note 8.0.

[More from BGR: BlackBerry 10 browser smokes iOS 6 and Windows Phone 8 in comparison test [video]]

With a footprint that measures 8.3 inches by 5.4 inches, the Galaxy Note 8.0 can be used comfortably with one hand but provides much more screen real estate than a 7-inch tablet. As this slate falls into Samsung’s Note lineup, it also includes an S Pen stylus and an updated suite of stylus-ready apps.

[More from BGR: The end of unlimited BBM could erode BlackBerry’s standing in emerging markets]

Samsung’s new 8-inch Note slides perfectly into the gap between the Galaxy Note II and the Galaxy Note 10.1. “It’s the best of both worlds,” Samsung Mobile’s director of product planning Shoneel Kolhatkar said during a briefing.

Key specs include an 8-inch 1280 x 800-pixel TFT display, a 1.6GHz quad-core processor, 2GB of RAM, 32GB or 64GB of internal storage, microSDXC support, a 4,600 mAh battery, Android 4.1.2 Jelly Bean and a sleek case that is 25% thinner that the Galaxy Note 10.1. The Note 8.0 also includes an integrated 3G antenna, but a Wi-Fi-only version will be available shortly after the 3G version launches.

While Samsung focused mainly on the consumer market with the first Galaxy Note tablet, The Note 8.0 is as much about enterprise as it is about consumers. ”The next big thing is being extended to business,” Samsung Electronics’ marketing boss Travis Merrill told reporters at a recent meeting in New York City. Great features like the ability to run multiple apps at once in different windows extends the slate’s utility in a business environment, and Samsung’s “SAFE” certification means the tablet is secure.

Other intriguing features include a new “Readers Mode,” which conserves battery, dims the screen and changes the tablet’s contrast settings to make it a great eReader, and a host of new second screen features that make the Note 8.0 a solid TV companion.

The Galaxy Note 8.0 will launch in a number of markets around the world including the United States beginning in the second quarter this year. Pricing has not yet been announced.

Samsung’s full press release follows below, and be sure to check out our hands-on impressions of Samsung’s new Galaxy Note 8.0 tablet.

INTRODUCING THE GALAXY NOTE 8.0,
A NEW ERA OF PORTABILITY AND EVERYDAY PRODUCTIVITY

SEOUL, Korea [February 24, 2011] – Samsung Electronics Co., Ltd, a global leader in digital media and digital convergence technologies, today announced the launch of the 8 inch tablet, the GALAXY Note 8.0; a new era of intelligent Note technology set to re-ignite the mid-size tablet category that Samsung established in 2010. Providing unrivalled multimedia performance within a compact one-hand-grip screen, the GALAXY Note 8.0 has the power and advanced technology to evolve the tablet experience and ensure you achieve new levels of efficient multi-tasking while benefitting from superb voice call functionality*. Furthermore, the intelligent S Pen brings together the latest innovation and the ease of using a traditional pen and paper; creating a sophisticated mobile experience that will enhance life on the go.

“Back in 2010 the launch of the first Samsung GALAXY Tab with 7 inch screen opened a new chapter in the mobile industry. Now almost three years later, Samsung continues to evolve the sector that meets the demands of modern life.” said JK Shin, President of the IT & Mobile Communications Division at Samsung Electronics.

“The GALAXY Note 8.0 breaths fresh life into the category as it delivers the perfect fusion of portability and everyday productivity – the result is a pioneering, pocket-sized solution that enhances and enriches our everyday lives, whether at work or play,” added Shin.

At the core of the GALAXY Note 8.0’s innovative solutions are beneficial functions, including multi-window options to split the portable 8inch screen and allow optimal access to a number of live applications; a new generation of Samsung’s intelligent S Pen with advanced usability; access to a suite of S Note templates and tools that allow you to create, edit, manage and share everyday documents; the Samsung “reading mode” technology to enjoy e books with optimized resolution, video and voice calls*. In addition, a suite of exciting new content and services are pre-loaded for users at no additional cost including, for the very first time on Samsung GALAXY tablet, the innovative Flipboard, and Awesome Note.

A smart diary for life on the go

Slim and compact enough to become the perfect on-the-go work and play companion, the GALAXY Note 8.0 brings powerful performance and functionality to support even the most demanding of lifestyles. Designed to store and manage your personal and professional data efficiently, the new era device gives users the perfect pocket-sized hands-on organizational tool. Practical S Note templates and S Planner feature help to manage everyday tasks, including meeting notes, to-do lists and even personal diary entries. All content can be entered and updated with the finest of detail thanks to the evolution of the intelligent Samsung S Pen. Enhanced precision is offered with Handwriting-to-Text conversion and advanced Productivity Tools that support formula and shape recognition are now available at the touch of your S Pen.

New content and services

GALAXY Note 8.0 is packed with pre-loaded content and apps specifically for the value maximizing, mass multimedia consumer. Upgraded Chat-On provides easy instant messaging and group chatting in multiple formats – images, video, voice, contacts – for simple, enjoyable communication. Awesome Note, an integrated application that is introduced in android tablet for the first time with NOTE 8.0, is capable of unlimited note-taking uses including Memo, Diary and Must-remember lists. With Flipboard, your news, social network and other feeds come together in one stylish, flippable format so you can enjoy all your news and life’s great moments in one place. Flipboard developed a customized version of its application exclusively for Samsung that allows users to take the S Pen’s hover feature and preview article headers beneath Flipboard’s main screen tiles. Finally, Smart Remote, gives you a universal remote control and electronic programming guide allowing you to manage TV and video watching seamlessly.

A new age of S Pen intelligence

Optimized to aid personalized creativity, the Samsung S Pen has evolved to increase everyday usability and enhance creation expression. Embedded within the tablet, the S Pen is an extension of the GALAXY Note 8.0. Removing the S Pen from the device will automatically launch innovative features such as Pen Detection that will suggest adapted menus that it thinks you’ll need and Page Buddy, a feature that will intuitively activate your most recently adapted S Note home screen.

S Pen technology is now so advanced that it doesn’t even have to touch the screen. With Air View, the S Pen needs only to hover over the screen to see previews of videos, emails, photos and appointments on SPlanner without opening the file or application in full. S Pen Gesture allows images and content to be easily edited and cropped, whilst Paper Artist and Photo Note allow photos to be artistically personalized.

In addition, for the very first time in GALAXY NOTE category, you can use S Pen to control the physical menu/back buttons on the device with WACOM technology.

Maximizing mass multimedia consumption

Creative multi-tasking with the GALAXY Note 8.0 is effortless due to innovative Dual View feature, two multi window options that seamlessly allow you to facilitate multi-screen usage. Dual View’s split screen accommodates optimal operation of different apps, such as launching the S Note on the web browser screen and allowing content to be resized, dragged and dropped as required.

Multi-tasking is extended to phone calls*. Pop Up Note allows you to access S Note at any time to keep track of key actions and Pop Up Video ensures you can keep surfing the web whilst chatting – content windows can be easily resized by pinching to enlarge or reduce.

Perfect info-tainment partner

Packed with features to engage, entertain and excite, the GALAXY Note 8.0 supports your practical everyday needs. Reading Mode transforms the GALAXY Note 8.0 into an e-Book reader, provides the optimal reading conditions to ensure you can curl up and enjoy a good book. You can even turn it into a universal remote control with Smart Remote, to seamlessly manage TVs, set-up boxes, DVD & Blu-ray players.

This article was originally published on BGR.com

Gadgets News Headlines – Yahoo! News

Title Post: Samsung sets sights on iPad mini with new Galaxy Note 8.0 tablet
Url Post: http://www.news.fluser.com/samsung-sets-sights-on-ipad-mini-with-new-galaxy-note-8-0-tablet/
Link To Post : Samsung sets sights on iPad mini with new Galaxy Note 8.0 tablet
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment

Read More..

See the Mini Balenciaga Bag Kim Kardashian Gifted Niece Penelope

Mom & Babies
Celebrity Baby Blog

02/22/2013 at 05:00 PM ET

Mom Kourtney Kardashian has one! Aunts Kim and Khloé own one too. And now Penelope Disick is the latest family member to add Balenciaga‘s chic city tote to her closet.

“Penelope is wearing the little Balenciaga bag that I got her for Christmas!” Kim posted on Instagram Friday, along with an adorable photo of the mom-to-be with her 7½-month-old niece and her mini yellow handbag.

Is Kim gearing up for her little one? If she has a little girl, we have no doubt her wardrobe will be the envy of the playground. Although the expectant reality star recently revealed that if it’s up to dad-to-be Kanye West, their baby will be wearing lots of “big chains and leather pants.”

And to be fair, Penelope wasn’t the only Kardashian-Jenner kid to receive luxe fashions for Christmas. Kylie and Kendall also scored during the holidays.

Courtesy Kim Kardashian; Inset: Rex USA

– Shanelle Rein-Olowokere

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Investors face another Washington deadline

NEW YORK (Reuters) - Investors face another Washington-imposed deadline on government spending cuts next week, but it's not generating the same level of fear as two months ago when the "fiscal cliff" loomed large.

Investors in sectors most likely to be affected by the cuts, like defense, seem untroubled that the budget talks could send stocks tumbling.

Talks on the U.S. budget crisis began again this week leading up to the March 1 deadline for the so-called sequestration when $85 billion in automatic federal spending cuts are scheduled to take effect.

"It's at this point a political hot button in Washington but a very low level investor concern," said Fred Dickson, chief market strategist at D.A. Davidson & Co. in Lake Oswego, Oregon. The fight pits President Barack Obama and fellow Democrats against congressional Republicans.

Stocks rallied in early January after a compromise temporarily avoided the fiscal cliff, and the Standard & Poor's 500 index <.spx> has risen 6.3 percent since the start of the year.

But the benchmark index lost steam this week, posting its first week of losses since the start of the year. Minutes on Wednesday from the last Federal Reserve meeting, which suggested the central bank may slow or stop its stimulus policy sooner than expected, provided the catalyst.

National elections in Italy on Sunday and Monday could also add to investor concern. Most investors expect a government headed by Pier Luigi Bersani to win and continue with reforms to tackle Italy's debt problems. However, a resurgence by former leader Silvio Berlusconi has raised doubts.

"Europe has been in the last six months less of a topic for the stock market, but the problems haven't gone away. This may bring back investor attention to that," said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.

OPTIONS BULLS TARGET GAINS

The spending cuts, if they go ahead, could hit the defense industry particularly hard.

Yet in the options market, bulls were targeting gains in Lockheed Martin Corp , the Pentagon's biggest supplier.

Calls on the stock far outpaced puts, suggesting that many investors anticipate the stock to move higher. Overall options volume on the stock was 2.8 times the daily average with 17,000 calls and 3,360 puts traded, according to options analytics firm Trade Alert.

"The upside call buying in Lockheed solidifies the idea that option investors are not pricing in a lot of downside risk in most defense stocks from the likely impact of sequestration," said Jared Woodard, a founder of research and advisory firm condoroptions.com in Forest, Virginia.

The stock ended up 0.6 percent at $88.12 on Friday.

If lawmakers fail to reach an agreement on reducing the U.S. budget deficit in the next few days, a sequester would include significant cuts in defense spending. Companies such as General Dynamics Corp and Smith & Wesson Holding Corp could be affected.

General Dynamics Corp shares rose 1.2 percent to $67.32 and Smith & Wesson added 4.6 percent to $9.18 on Friday.

EYES ON GDP DATA, APPLE

The latest data on fourth-quarter U.S. gross domestic product is expected on Thursday, and some analysts predict an upward revision following trade data that showed America's deficit shrank in December to its narrowest in nearly three years.

U.S. GDP unexpectedly contracted in the fourth quarter, according to an earlier government estimate, but analysts said there was no reason for panic, given that consumer spending and business investment picked up.

Investors will be looking for any hints of changes in the Fed's policy of monetary easing when Fed Chairman Ben Bernake speaks before congressional committees on Tuesday and Wednesday.

Shares of Apple will be watched closely next week when the company's annual stockholders' meeting is held.

On Friday, a U.S. judge handed outspoken hedge fund manager David Einhorn a victory in his battle with the iPhone maker, blocking the company from moving forward with a shareholder vote on a controversial proposal to limit the company's ability to issue preferred stock.

(Additional reporting by Doris Frankel; Editing by Kenneth Barry)

Read More..